UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

Advances in therapy, 2023-10, Vol.40 (10), p.4189-4215

2023

Volltextzugriff (PDF)

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

Journal of clinical oncology, 2011-01, Vol.29 (3), p.287-293

2011

Volltextzugriff (PDF)

Thrombosis in acute promyelocytic leukemia

Thrombosis research, 2013-04, Vol.131 (4), p.281-289

2013

Volltextzugriff (PDF)

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

Cancer chemotherapy and pharmacology, 2021-05, Vol.87 (5), p.689-700

2021

Volltextzugriff (PDF)

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2598-2603

2010

Volltextzugriff (PDF)

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

Cancer chemotherapy and pharmacology, 2021-01, Vol.87 (1), p.135-144

2021

Volltextzugriff (PDF)

Acute promyelocytic leukemia following solid organ transplantation

Annals of hematology, 2016-01, Vol.95 (1), p.169-171

2016

Volltextzugriff (PDF)

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Clinical colorectal cancer, 2012-06, Vol.11 (2), p.101-111

2012

Volltextzugriff (PDF)

A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

The oncologist (Dayton, Ohio), 2013-03, Vol.18 (3), p.271-272

2013

Volltextzugriff (PDF)

PP01.11 Real-world treatment patterns and outcomes among unresectable Stage III Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e13-e13

2024

Volltextzugriff (PDF)

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

Investigational new drugs, 2015-02, Vol.33 (1), p.148-158

2015

Volltextzugriff (PDF)

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1360-1370

2021

Volltextzugriff (PDF)

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.101-108

2011

Volltextzugriff (PDF)

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Volltextzugriff (PDF)

36 Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and Vascular Endothelial Growth Factor (VEGF) receptor targeted therapies

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S22-S23

2024

Volltextzugriff (PDF)

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Lung cancer (Amsterdam, Netherlands), 2019-02, Vol.128, p.105-112

2019

Volltextzugriff (PDF)

Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6629-6629

2023

Volltextzugriff (PDF)

US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.483-483

2023

Volltextzugriff (PDF)

Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.560-560

2024

Volltextzugriff (PDF)

Abstract 1774: Examination of variants of unknown significance (VUSs) and co-occurring mutations from comprehensive genomic profiling (CGP) results in a cross tumor model

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1774-1774

2024

Volltextzugriff (PDF)

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Clinical cancer research, 2021-06, Vol.27 (12), p.3360-3369

2021

Volltextzugriff (PDF)

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Clinical cancer research, 2014-07, Vol.20 (13), p.3581-3588

2014

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Oncology
(25)
Female
(22)
Middle Aged
(22)
Aged
(21)
Male
(20)
Adult
(19)
Aged, 80 And Over
(16)
Biological And Medical Sciences
(14)
Tumors
(13)
Medical Sciences
(12)
Treatment Outcome
(10)
Lung Neoplasms - Drug Therapy
(9)
Medicine
(9)
Medicine & Public Health
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Dose-Response Relationship, Drug
(8)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

Thrombosis in acute promyelocytic leukemia

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

Acute promyelocytic leukemia following solid organ transplantation

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

PP01.11 Real-world treatment patterns and outcomes among unresectable Stage III Non-Small Cell Lung Cancer

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

36 Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and Vascular Endothelial Growth Factor (VEGF) receptor targeted therapies

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting

US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval

Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network

Abstract 1774: Examination of variants of unknown significance (VUSs) and co-occurring mutations from comprehensive genomic profiling (CGP) results in a cross tumor model

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Suchergebnisse filtern